Israel - hebreiska - Ministry of Health

neopharm (israel) 1996 ltd - glucose as monohydrate 10 % - solution for injection - glucose - fluid adn nutrient replenishment.

Israel - hebreiska - Ministry of Health

neopharm (israel) 1996 ltd - sodium chloride 0.9 g / 100 ml - solution for injection - sodium chloride - vehicle for therapeutic regimen. balance restoration (chloride + sodium). extracellular dehydration. hypovolaemia.

Israel - hebreiska - Ministry of Health

neopharm (israel) 1996 ltd - sodium chloride - תמיסה להזרקה - sodium chloride 0.45 g / 100 ml - sodium chloride - sodium chloride - supply of water for administration of electrolytes. vehicle for therapeutic regimen.

Israel - hebreiska - Ministry of Health

neopharm (israel) 1996 ltd - calcium chloride 27 mg / 100 ml; lactic acid as sodium 0.533 g / 100 ml - solution for injection - combinations of electrolytes - isotonic injectable solution.

Israel - hebreiska - Ministry of Health

unipharm ltd, israel - cilazapril - טבליה - cilazapril 2.5 mg - cilazapril - cilazapril - a blood pressure lowering agent. chronic heart failure.

Israel - hebreiska - Ministry of Health

unipharm ltd, israel - cilazapril - טבליה - cilazapril 5 mg - cilazapril - cilazapril - a blood pressure lowering agent. chronic heart failure.

Israel - hebreiska - Ministry of Health

unipharm ltd, israel - cilazapril; hydrochlorothiazide - טבליה - cilazapril 5 mg; hydrochlorothiazide 12.5 mg - cilazapril - cilazapril - treatment of essential hypertension in patients who have been stabilized on the individual components given in the same proportions.

Israel - hebreiska - Ministry of Health

unipharm ltd, israel - cilazapril - טבליה - cilazapril 1 mg - cilazapril - cilazapril - a blood pressure lowering agent.chronic heart failure.

Israel - hebreiska - Ministry of Health

unipharm ltd, israel - atorvastatin as calcium trihydrate salt - טבליה - atorvastatin as calcium trihydrate salt 10 mg - atorvastatin - atorvastatin - torid is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. torid is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable. pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190 mg/

Israel - hebreiska - Ministry of Health

unipharm ltd, israel - atorvastatin as calcium trihydrate salt - טבליה - atorvastatin as calcium trihydrate salt 20 mg - atorvastatin - atorvastatin - torid is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. torid is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable. pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190 mg/